CN114846012B - 可用作hdac6抑制剂的2-异吲哚-1,3,4-噁二唑衍生物 - Google Patents

可用作hdac6抑制剂的2-异吲哚-1,3,4-噁二唑衍生物 Download PDF

Info

Publication number
CN114846012B
CN114846012B CN202080068097.3A CN202080068097A CN114846012B CN 114846012 B CN114846012 B CN 114846012B CN 202080068097 A CN202080068097 A CN 202080068097A CN 114846012 B CN114846012 B CN 114846012B
Authority
CN
China
Prior art keywords
compound
group
optionally substituted
mixture
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080068097.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN114846012A (zh
Inventor
伊东昌宏
杉山英之
山本武志
挂川佳子
李金星
王俊思
笠原敬仁
吉川真人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CN114846012A publication Critical patent/CN114846012A/zh
Application granted granted Critical
Publication of CN114846012B publication Critical patent/CN114846012B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080068097.3A 2019-09-27 2020-09-24 可用作hdac6抑制剂的2-异吲哚-1,3,4-噁二唑衍生物 Active CN114846012B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019177815 2019-09-27
JP2019-177815 2019-09-27
PCT/JP2020/037386 WO2021060567A1 (en) 2019-09-27 2020-09-24 2-isoindol-1,3,4-oxadiazole derivatives useful as hdac6 inhibitors

Publications (2)

Publication Number Publication Date
CN114846012A CN114846012A (zh) 2022-08-02
CN114846012B true CN114846012B (zh) 2024-01-26

Family

ID=73040188

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080068097.3A Active CN114846012B (zh) 2019-09-27 2020-09-24 可用作hdac6抑制剂的2-异吲哚-1,3,4-噁二唑衍生物

Country Status (19)

Country Link
US (3) US11453661B2 (enExample)
EP (1) EP4034536A1 (enExample)
JP (1) JP7602546B2 (enExample)
KR (1) KR20220070465A (enExample)
CN (1) CN114846012B (enExample)
AR (1) AR120040A1 (enExample)
AU (1) AU2020353984B2 (enExample)
BR (1) BR112022005595A2 (enExample)
CA (1) CA3156060A1 (enExample)
CL (1) CL2022000763A1 (enExample)
CO (1) CO2022005059A2 (enExample)
EC (1) ECSP22026524A (enExample)
IL (1) IL291413B2 (enExample)
MX (1) MX2022003490A (enExample)
PE (1) PE20220711A1 (enExample)
PH (1) PH12022550748A1 (enExample)
TW (1) TWI882012B (enExample)
WO (1) WO2021060567A1 (enExample)
ZA (1) ZA202204666B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
CN114727974A (zh) 2019-07-30 2022-07-08 艾科尼佐治疗股份有限公司 Hdac6抑制剂及其用途
CN114846012B (zh) * 2019-09-27 2024-01-26 武田药品工业株式会社 可用作hdac6抑制剂的2-异吲哚-1,3,4-噁二唑衍生物
KR20220119653A (ko) 2019-12-20 2022-08-30 테나야 테라퓨틱스, 인코포레이티드 플루오로알킬-옥사디아졸 및 이의 용도
WO2022169985A1 (en) 2021-02-03 2022-08-11 Eikonizo Therapeutics, Inc. Hdac6 inhibitors and uses thereof
EP4326263A1 (en) 2021-04-23 2024-02-28 Tenaya Therapeutics, Inc. Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy
US20240252502A1 (en) 2021-05-04 2024-08-01 Tenaya Therapeutics, Inc. Hdac6 inhibitors for treatment of metabolic disease and hfpef
CN114166824B (zh) * 2021-12-08 2024-01-23 桂林医学院 一种辅剂示踪分析保健品中药物含量的方法
AU2023250964A1 (en) 2022-04-08 2024-11-07 Eikonizo Therapeutics, Inc. Oxadiazole hdac6 inhibitors and uses thereof
EP4509506A4 (en) * 2022-04-15 2026-03-25 Suzhou Genhouse Bio Co Ltd OXADIAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING IT AND ITS USAGE
EP4685143A1 (en) * 2023-03-21 2026-01-28 Vivozon,Inc. Double regulator for mglur5 and hdac6 and use thereof
KR102972943B1 (ko) * 2023-08-22 2026-06-02 전남대학교산학협력단 신경세포로의 분화 촉진용 조성물
CN121969616A (zh) * 2023-09-28 2026-05-01 勤浩医药(苏州)股份有限公司 一种hdac6抑制剂的结晶形式及其制备方法
WO2025215092A1 (en) 2024-04-10 2025-10-16 Institut National de la Santé et de la Recherche Médicale Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1
CN119823019A (zh) * 2025-01-06 2025-04-15 沈阳药科大学 一种具有治疗特发性肺纤维化作用的吲哚类化合物及其制备方法和应用

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101056632A (zh) * 2004-11-09 2007-10-17 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
CN102770412A (zh) * 2009-12-22 2012-11-07 细胞基因公司 (甲基磺酰基)乙基苯异吲哚啉衍生物及其治疗应用
WO2013009810A1 (en) * 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
AU2013203735A1 (en) * 2007-12-04 2013-05-02 F. Hoffmann-La Roche Ag Isoxazolo-pyridine derivatives
CN105120860A (zh) * 2013-03-15 2015-12-02 生物马林药物股份有限公司 组蛋白脱乙酰酶抑制剂
CN106232584A (zh) * 2014-03-12 2016-12-14 株式会社钟根堂 作为组蛋白脱乙酰酶6抑制剂的新型化合物和包含其的药物组合物
WO2017222952A1 (en) * 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
CN107873023A (zh) * 2015-02-02 2018-04-03 福马治疗股份有限公司 作为hdac抑制剂的3‑烷基‑4‑酰氨基‑双环[4，5，0]异羟肟酸
AU2016338118A1 (en) * 2015-10-12 2018-04-12 Chong Kun Dang Pharmaceutical Corp. Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
CN107980040A (zh) * 2015-07-27 2018-05-01 株式会社钟根堂 作为组蛋白去乙酰酶6抑制剂的1,3,4-噁二唑磺酰胺衍生物及含其的医药组合物
CN108026088A (zh) * 2015-07-17 2018-05-11 武田药品工业株式会社 用作hdac抑制剂的噁二唑衍生物
WO2019027054A1 (en) * 2017-07-31 2019-02-07 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US20040142859A1 (en) 2002-05-02 2004-07-22 Steffan Joan S. Method for treating neurodegenerative, psychiatric, and other disorders with deacetylase inhibitors
DE60227658D1 (de) 2001-05-02 2008-08-28 Univ California Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
US20050227915A1 (en) 2001-05-02 2005-10-13 Steffan Joan S Methods and reagents for treating neurodegenerative diseases and motor deficit disorders
EP1443928B1 (en) 2001-10-16 2011-07-27 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
MXPA04008577A (es) 2002-03-04 2005-07-13 Aton Pharma Inc Metodos para inducir diferenciacion terminal.
AU2003244713A1 (en) 2002-03-26 2003-10-08 Exonhit Therapeutics S.A. Histone deacetylase: novel molecular target of neurotoxicity
WO2003083067A2 (en) 2002-03-28 2003-10-09 Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
ITMI20040876A1 (it) 2004-04-30 2004-07-30 Univ Degli Studi Milano Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari
US20060018921A1 (en) 2004-07-16 2006-01-26 Baylor College Of Medicine Histone deacetylase inhibitors and cognitive applications
GT200500321A (es) 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
US20060135612A1 (en) 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
SG171690A1 (en) 2005-03-22 2011-06-29 Harvard College Treatment of protein degradation disorders
CN101267779A (zh) 2005-07-27 2008-09-17 福罗里达大学研究基金会有限公司 使用热休克治疗眼睛疾病
CA2621560A1 (en) 2005-09-07 2007-03-15 Braincells, Inc. Modulation of neurogenesis by hdac inhibition
WO2007049262A1 (en) 2005-10-27 2007-05-03 Berand Limited Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders
CA2626897A1 (en) 2005-11-03 2007-05-18 Joshua Close Histone deacetylase inhibitors with aryl-pyrazolyl motifs
US20070207950A1 (en) 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
GB0612273D0 (en) 2006-06-21 2006-08-02 Friedrich Miescher Inst For Bi Prevention of muscle atrophy
US8088951B2 (en) 2006-11-30 2012-01-03 Massachusetts Institute Of Technology Epigenetic mechanisms re-establish access to long-term memory after neuronal loss
WO2008073733A1 (en) 2006-12-08 2008-06-19 Kalypsys, Inc. Salts of inhibitors of histone deacetylase for the treatment of disease
MX2009006327A (es) 2006-12-15 2009-06-23 Novartis Ag Compuestos heterociclicos y metodos de uso de los mismos.
WO2008126932A2 (en) 2007-04-09 2008-10-23 Riken Epigenetical regulation of brain plasticity
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
EP2195029A2 (en) 2007-08-24 2010-06-16 Oryzon Genomics SA Treatment and prevention of neurodegenerative diseases
US20090136461A1 (en) 2007-11-28 2009-05-28 Moon Suk Kim Neuronal differentiation method of adult stem cells using small molecules
KR101781663B1 (ko) 2010-01-13 2017-09-25 템페로 파마슈티칼즈, 인크. 히스톤 데아세틸라제 효소를 억제하기 위한 화합물 및 이를 제조하는 방법
EP2523664A4 (en) 2010-01-13 2013-06-26 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
WO2012018499A2 (en) 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
CA2812855C (en) 2010-10-08 2017-12-19 Vib Vzw Hdac inhibitors to treat charcot-marie-tooth disease
WO2012058128A2 (en) 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Caprolactam mglur5 receptor modulators
WO2012118782A1 (en) 2011-02-28 2012-09-07 Repligen Corporation Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
WO2012149540A1 (en) 2011-04-28 2012-11-01 The Broad Institute Inc Inhibitors of histone deacetylase
US20140235649A1 (en) 2011-05-24 2014-08-21 Lixte Biotechnology, Inc. Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function
WO2013006408A1 (en) 2011-07-01 2013-01-10 Tempero Pharmaceuticals, Inc. Compounds and methods
EA201490228A1 (ru) 2011-07-08 2014-08-29 Новартис Аг Новые производные трифторметилоксадиазола и их применение для лечения заболевания
WO2013009830A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009827A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
EP2734500A4 (en) 2011-07-20 2015-04-08 Gen Hospital Corp SELECTIVE HISTONDEACETYLASE-6 INHIBITORS FOR THE TREATMENT OF BONE DISORDERS
WO2013066839A2 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066833A1 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods to inhibit histone deacetylase (hdac) enzymes
WO2013066835A2 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066831A1 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066838A1 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
CA2856334A1 (en) 2011-11-28 2013-06-06 Christina Hebach Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
WO2013149091A1 (en) 2012-03-29 2013-10-03 The Regents Of The University Of Colorado, A Body Corporate Composition and method for treating neurodegenerative disease
US20150119327A1 (en) 2012-04-25 2015-04-30 The Regents Of The University Of California Drug screening platform for rett syndrome
US20150184154A1 (en) 2012-07-05 2015-07-02 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear New treatment for neurodegenerative diseases
CN104894060B (zh) 2014-03-03 2018-11-06 中国科学院上海生命科学研究院 诱导体细胞转分化为神经干细胞的方法及其应用
EP3187497A4 (en) 2014-08-26 2018-02-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
JPWO2016039398A1 (ja) 2014-09-09 2017-06-15 国立大学法人大阪大学 含窒素複素環誘導体、神経保護剤及び癌治療用医薬組成物
CN107848695A (zh) 2015-06-30 2018-03-27 Wm.雷格利 Jr.公司 用于糖果产品的包装和用于形成该包装的方法
US10357484B2 (en) 2015-07-17 2019-07-23 Takeda Pharmaceutical Company Limited Heterocyclic compound
HRP20230052T1 (hr) 2015-07-27 2023-03-03 Chong Kun Dang Pharmaceutical Corp. Spojevi derivata 1,3,4-oksadiazol sulfonamida kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži
NZ739211A (en) 2015-07-27 2019-05-31 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
HRP20220003T1 (hr) 2015-08-04 2022-04-01 Chong Kun Dang Pharmaceutical Corp. Spojevi derivata 1,3,4-oksadiazola kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži
WO2017033946A1 (ja) 2015-08-25 2017-03-02 武田薬品工業株式会社 複素環化合物
US20180016314A1 (en) 2016-07-12 2018-01-18 Children's Hospital Medical Center Treatment of disease via transcription factor modulation
US10357493B2 (en) * 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
WO2018215597A1 (en) 2017-05-24 2018-11-29 Orphazyme A/S Heat shock protein inducers and frontotemporal disorders
WO2019032652A1 (en) 2017-08-09 2019-02-14 Children's Hospital Medical Center METHODS OF TREATING DISEASES AND NERVE INJURIES
US20200216563A1 (en) 2017-08-10 2020-07-09 Friedrich Miescher Institute For Biomedical Research Hdac6 and protein aggregation
JP6910984B2 (ja) 2018-03-30 2021-07-28 株式会社ホンダアクセス 脱出ハンマー収容具
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
RS66346B1 (sr) 2018-10-22 2025-01-31 Alumis Inc Inhibitori tyk2 i njihova upotreba
EP3919055A4 (en) 2019-01-30 2022-11-09 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND
CN114846012B (zh) * 2019-09-27 2024-01-26 武田药品工业株式会社 可用作hdac6抑制剂的2-异吲哚-1,3,4-噁二唑衍生物

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101056632A (zh) * 2004-11-09 2007-10-17 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
AU2013203735A1 (en) * 2007-12-04 2013-05-02 F. Hoffmann-La Roche Ag Isoxazolo-pyridine derivatives
CN102770412A (zh) * 2009-12-22 2012-11-07 细胞基因公司 (甲基磺酰基)乙基苯异吲哚啉衍生物及其治疗应用
WO2013009810A1 (en) * 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
CN105120860A (zh) * 2013-03-15 2015-12-02 生物马林药物股份有限公司 组蛋白脱乙酰酶抑制剂
CN106232584A (zh) * 2014-03-12 2016-12-14 株式会社钟根堂 作为组蛋白脱乙酰酶6抑制剂的新型化合物和包含其的药物组合物
CN107873023A (zh) * 2015-02-02 2018-04-03 福马治疗股份有限公司 作为hdac抑制剂的3‑烷基‑4‑酰氨基‑双环[4，5，0]异羟肟酸
CN108026088A (zh) * 2015-07-17 2018-05-11 武田药品工业株式会社 用作hdac抑制剂的噁二唑衍生物
CN107980040A (zh) * 2015-07-27 2018-05-01 株式会社钟根堂 作为组蛋白去乙酰酶6抑制剂的1,3,4-噁二唑磺酰胺衍生物及含其的医药组合物
AU2016338118A1 (en) * 2015-10-12 2018-04-12 Chong Kun Dang Pharmaceutical Corp. Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
WO2017222952A1 (en) * 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2019027054A1 (en) * 2017-07-31 2019-02-07 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"组蛋白去乙酰化酶6 选择性抑制剂的研究进展";马宇 等;《国际药学研究杂志》;第45卷(第11期);第824-833页 *
"组蛋白去乙酰化酶6在阿尔茨海默病中的作用";陆剑平 等;《国际神经病学神经外科学杂志》;第38卷(第4期);第348-352页 *
"组蛋白去乙酰化酶6的结构、功能及选择性抑制剂的研究进展";刘仁帅 等;《药学学报》;第50卷(第1期);第7-14页 *

Also Published As

Publication number Publication date
US12384770B2 (en) 2025-08-12
CO2022005059A2 (es) 2022-07-08
AU2020353984B2 (en) 2025-09-25
TW202126643A (zh) 2021-07-16
US20240343721A1 (en) 2024-10-17
MX2022003490A (es) 2022-04-25
ZA202204666B (en) 2023-11-29
WO2021060567A1 (en) 2021-04-01
US20230183227A1 (en) 2023-06-15
TWI882012B (zh) 2025-05-01
US20210094944A1 (en) 2021-04-01
BR112022005595A2 (pt) 2022-07-19
AU2020353984A1 (en) 2022-04-21
AU2020353984A2 (en) 2022-08-04
PH12022550748A1 (en) 2023-11-20
IL291413B1 (en) 2024-11-01
JP7602546B2 (ja) 2024-12-18
CL2022000763A1 (es) 2023-01-20
US11453661B2 (en) 2022-09-27
PE20220711A1 (es) 2022-05-04
EP4034536A1 (en) 2022-08-03
CA3156060A1 (en) 2021-04-01
JP2022552444A (ja) 2022-12-15
KR20220070465A (ko) 2022-05-31
ECSP22026524A (es) 2022-05-31
CN114846012A (zh) 2022-08-02
IL291413B2 (en) 2025-03-01
US11958845B2 (en) 2024-04-16
AR120040A1 (es) 2022-01-26
IL291413A (en) 2022-05-01

Similar Documents

Publication Publication Date Title
JP7602546B2 (ja) Ｈｄａｃ６阻害剤として有用な２－イソインドール－１，３，４－オキサジアゾール誘導体
JP7470058B2 (ja) 複素環化合物
TW201910328A (zh) 雜環化合物
US12378256B2 (en) Heterocyclic compound
JPWO2019022179A1 (ja) 複素環化合物
EP3915638A1 (en) Heterocyclic compound and use thereof
CN112752760B (zh) 杂环化合物
JP7250687B2 (ja) 複素環化合物
EP4034257B1 (en) Heterocyclic compound and use thereof
KR102658949B1 (ko) 헤테로시클릭 화합물
US11970483B2 (en) Heterocyclic compound
EA045216B1 (ru) Производные 2-изоиндол-1,3,4-оксадиазола, применимые в качестве ингибиторов hdac6
HK40077256A (en) Heterocyclic compound and use thereof
HK40077256B (en) Heterocyclic compound and use thereof
EP3858823A1 (en) Condensed-cyclic compound
HK40059391A (en) Heterocyclic compound and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant